BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007;51:1725-30. [PMID: 17307978 DOI: 10.1128/AAC.00294-06] [Cited by in Crossref: 179] [Cited by in F6Publishing: 75] [Article Influence: 11.9] [Reference Citation Analysis]
Number Citing Articles
1 Pais GM, Chang J, Barreto EF, Stitt G, Downes KJ, Alshaer MH, Lesnicki E, Panchal V, Bruzzone M, Bumanglag AV, Burke SN, Scheetz MH. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet 2022. [PMID: 35764774 DOI: 10.1007/s40262-022-01137-y] [Reference Citation Analysis]
2 Stitt G, Dubinsky S, Edginton A, Huang YV, Zuppa AF, Watt K, Downes K. Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence. Front Pediatr 2022;10:889958. [DOI: 10.3389/fped.2022.889958] [Reference Citation Analysis]
3 Mabilat C, Gros MF, Nicolau D, Mouton JW, Textoris J, Roberts JA, Cotta MO, van Belkum A, Caniaux I. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol Infect Dis 2020;39:791-7. [PMID: 31828686 DOI: 10.1007/s10096-019-03769-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
4 De Waele JJ, Lipman J, Akova M, Bassetti M, Dimopoulos G, Kaukonen M, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Udy AA, Starr T, Wallis SC, Roberts JA. Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Med 2014;40:1340-51. [PMID: 25053248 DOI: 10.1007/s00134-014-3403-8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 92] [Article Influence: 12.9] [Reference Citation Analysis]
5 Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012;16:R113. [PMID: 22742765 DOI: 10.1186/cc11405] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
6 Weinelt FA, Stegemann MS, Theloe A, Pfäfflin F, Achterberg S, Schmitt L, Huisinga W, Michelet R, Hennig S, Kloft C. Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units. Pharmaceutics 2021;13:2128. [PMID: 34959409 DOI: 10.3390/pharmaceutics13122128] [Reference Citation Analysis]
7 Zhou QT, He B, Zhang C, Zhai SD, Liu ZY, Zhang J. Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging 2011;28:903-12. [PMID: 22054231 DOI: 10.2165/11595960-000000000-00000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
8 Wong G, Farkas A, Sussman R, Daroczi G, Hope WW, Lipman J, Roberts JA. Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrob Agents Chemother 2015;59:1411-7. [PMID: 25512414 DOI: 10.1128/AAC.04001-14] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care 2012;2:35. [PMID: 22839761 DOI: 10.1186/2110-5820-2-35] [Cited by in Crossref: 110] [Cited by in F6Publishing: 92] [Article Influence: 11.0] [Reference Citation Analysis]
10 Weinelt FA, Stegemann MS, Theloe A, Pfäfflin F, Achterberg S, Weber F, Dübel L, Mikolajewska A, Uhrig A, Kiessling P, Huisinga W, Michelet R, Hennig S, Kloft C. Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools. Antibiotics 2022;11:758. [DOI: 10.3390/antibiotics11060758] [Reference Citation Analysis]
11 Nonoshita K, Suzuki Y, Tanaka R, Kaneko T, Ohchi Y, Sato Y, Yasuda N, Goto K, Kitano T, Itoh H. Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit. Sci Rep 2020;10:22148. [PMID: 33335198 DOI: 10.1038/s41598-020-79076-6] [Reference Citation Analysis]
12 Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, Kirkpatrick CM, Kruger PS, Paterson DL, Roberts MS, Roberts JA. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 2015;19:28. [PMID: 25632974 DOI: 10.1186/s13054-015-0750-y] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 11.0] [Reference Citation Analysis]
13 Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014;14:498-509. [PMID: 24768475 DOI: 10.1016/S1473-3099(14)70036-2] [Cited by in Crossref: 474] [Cited by in F6Publishing: 183] [Article Influence: 59.3] [Reference Citation Analysis]
14 Saito J, Shoji K, Oho Y, Kato H, Matsumoto S, Aoki S, Nakamura H, Ogawa T, Hasegawa M, Yamatani A, Miyairi I. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients. Antimicrob Agents Chemother 2021;65:e01909-20. [PMID: 33199385 DOI: 10.1128/AAC.01909-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wong G, Sime FB, Lipman J, Roberts JA. How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients? BMC Infect Dis 2014;14:288. [PMID: 25430961 DOI: 10.1186/1471-2334-14-288] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 7.8] [Reference Citation Analysis]
16 Selig DJ, Akers KS, Chung KK, Pruskowski KA, Livezey JR, Por ED. Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno-venous hemofiltration. Br J Clin Pharmacol 2021. [PMID: 34773921 DOI: 10.1111/bcp.15138] [Reference Citation Analysis]
17 Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E, Depuydt P, Decruyenaere J, Lipman J, Wallis SC, De Waele JJ. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013;17:R84. [PMID: 23642005 DOI: 10.1186/cc12705] [Cited by in Crossref: 117] [Cited by in F6Publishing: 115] [Article Influence: 13.0] [Reference Citation Analysis]
18 Cojutti P, Sartor A, Righi E, Scarparo C, Bassetti M, Pea F. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2017;61:e00794-17. [PMID: 28760900 DOI: 10.1128/AAC.00794-17] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
19 Gijsen M, Dreesen E, Annaert P, Nicolai J, Debaveye Y, Wauters J, Spriet I. Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis. Microorganisms 2021;9:1310. [PMID: 34208553 DOI: 10.3390/microorganisms9061310] [Reference Citation Analysis]
20 Roberts JA, Roger C, De Waele JJ. Personalized antibiotic dosing for the critically ill. Intensive Care Med 2019;45:715-8. [PMID: 30637444 DOI: 10.1007/s00134-019-05522-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
21 Yadav R, Bergen PJ, Rogers KE, Kirkpatrick CMJ, Wallis SC, Huang Y, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. Antimicrob Agents Chemother 2019;64:e01679-19. [PMID: 31636062 DOI: 10.1128/AAC.01679-19] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 2016;56:56-66. [PMID: 26096377 DOI: 10.1002/jcph.566] [Cited by in Crossref: 101] [Cited by in F6Publishing: 94] [Article Influence: 14.4] [Reference Citation Analysis]
23 Abdul-Aziz MH, Lipman J, Roberts JA. Identifying "at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. Crit Care 2017;21:283. [PMID: 29157264 DOI: 10.1186/s13054-017-1871-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
24 Pea F, Viale P, Cojutti P, Furlanut M. Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother 2012;56:6343-8. [PMID: 23045356 DOI: 10.1128/AAC.01291-12] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
25 Ehmann L, Zoller M, Minichmayr IK, Scharf C, Maier B, Schmitt MV, Hartung N, Huisinga W, Vogeser M, Frey L, Zander J, Kloft C. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study. Crit Care 2017;21:263. [PMID: 29058601 DOI: 10.1186/s13054-017-1829-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
26 Roberts JA, De Waele JJ, Dimopoulos G, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 2012;12:152. [PMID: 22768873 DOI: 10.1186/1471-2334-12-152] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
27 Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrob Agents Chemother 2018;62:e00078-18. [PMID: 29463528 DOI: 10.1128/AAC.00078-18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
28 Olbrisch K, Kisch T, Thern J, Kramme E, Rupp J, Graf T, Wicha SG, Mailänder P, Raasch W. After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients. Naunyn Schmiedebergs Arch Pharmacol 2019;392:229-41. [PMID: 30368548 DOI: 10.1007/s00210-018-1573-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
29 Cheng V, Abdul-Aziz MH, Burrows F, Buscher H, Cho YJ, Corley A, Diehl A, Gilder E, Jakob SM, Kim HS, Levkovich BJ, Lim SY, McGuinness S, Parke R, Pellegrino V, Que YA, Reynolds C, Rudham S, Wallis SC, Welch SA, Zacharias D, Fraser JF, Shekar K, Roberts JA; ASAP ECMO Investigators. Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. Antimicrob Agents Chemother 2021;65:e0143821. [PMID: 34460303 DOI: 10.1128/AAC.01438-21] [Reference Citation Analysis]
30 Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15:R137. [PMID: 21649882 DOI: 10.1186/cc10257] [Cited by in Crossref: 144] [Cited by in F6Publishing: 139] [Article Influence: 13.1] [Reference Citation Analysis]
31 . Should IV Antibiotics Be Administered by Prolonged Infusion? Can J Hosp Pharm 2010;63:246-9. [PMID: 22478986 DOI: 10.4212/cjhp.v63i3.922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
32 Udy AA, Roberts JA, Lipman J, Blot S. The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. Adv Drug Deliv Rev 2018;123:65-74. [PMID: 28964882 DOI: 10.1016/j.addr.2017.09.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
33 Matusik E, Lambiotte F, Tone A, Lemtir J. [Pharmacokinetic modifications and pharmacokinetic/pharmacodynamic optimization of beta-lactams in ICU]. Ann Pharm Fr 2021;79:346-60. [PMID: 33309603 DOI: 10.1016/j.pharma.2020.11.011] [Reference Citation Analysis]
34 Hanberg P, Öbrink-Hansen K, Thorsted A, Bue M, Tøttrup M, Friberg LE, Hardlei TF, Søballe K, Gjedsted J. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment. Antimicrob Agents Chemother 2018;62:e02390-17. [PMID: 29530848 DOI: 10.1128/AAC.02390-17] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
35 Cojutti P, Maximova N, Pea F. Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients. Antimicrob Agents Chemother 2015;59:5535-41. [PMID: 26124157 DOI: 10.1128/AAC.00787-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
36 Roberts JA, Taccone FS, Lipman J. Understanding PK/PD. Intensive Care Med 2016;42:1797-800. [PMID: 26334756 DOI: 10.1007/s00134-015-4032-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
37 Scharf C, Paal M, Schroeder I, Vogeser M, Draenert R, Irlbeck M, Zoller M, Liebchen U. Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical Practice. Antibiotics (Basel) 2020;9:E131. [PMID: 32245195 DOI: 10.3390/antibiotics9030131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
38 Hagihara M, Kato H, Sugano T, Okade H, Sato N, Shibata Y, Sakanashi D, Hirai J, Asai N, Suematsu H, Yamagishi Y, Mikamo H. In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model. Antibiotics (Basel) 2021;10:1179. [PMID: 34680760 DOI: 10.3390/antibiotics10101179] [Reference Citation Analysis]
39 Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012;73:27-36. [PMID: 21831196 DOI: 10.1111/j.1365-2125.2011.04080.x] [Cited by in F6Publishing: 162] [Reference Citation Analysis]
40 Chua NG, Loo L, Hee DKH, Lim TP, Ng TM, Hoo GSR, Soong JL, Ong JCL, Tang SSL, Zhou YP, Lee W, Lee LS, Cove M, Ling LM, Kwa AL. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1). J Crit Care 2022;68:107-13. [PMID: 34999376 DOI: 10.1016/j.jcrc.2021.12.013] [Reference Citation Analysis]
41 Song X, Wu Y, Cao L, Yao D, Long M. Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation. Front Microbiol 2019;10:2777. [PMID: 31849910 DOI: 10.3389/fmicb.2019.02777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
42 Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, Roberts JA, Schouten J, Giamarellou H, Rello J, De Waele J, Shorr AF, Leone M, Poulakou G, Depuydt P, Garnacho-Montero J. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med 2020;46:245-65. [PMID: 31781835 DOI: 10.1007/s00134-019-05866-w] [Cited by in Crossref: 28] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
43 Urbina T, Razazi K, Ourghanlian C, Woerther PL, Chosidow O, Lepeule R, de Prost N. Antibiotics in Necrotizing Soft Tissue Infections. Antibiotics (Basel) 2021;10:1104. [PMID: 34572686 DOI: 10.3390/antibiotics10091104] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kuti JL, Kim A, Cloutier DJ, Nicolau DP. Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). Infect Dis Ther 2019;8:383-96. [PMID: 31254273 DOI: 10.1007/s40121-019-0251-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
45 Guilhaumou R, Benaboud S, Bennis Y, Dahyot-Fizelier C, Dailly E, Gandia P, Goutelle S, Lefeuvre S, Mongardon N, Roger C, Scala-Bertola J, Lemaitre F, Garnier M. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care 2019;23:104. [PMID: 30925922 DOI: 10.1186/s13054-019-2378-9] [Cited by in Crossref: 95] [Cited by in F6Publishing: 88] [Article Influence: 31.7] [Reference Citation Analysis]
46 Öbrink-Hansen K, Juul RV, Storgaard M, Thomsen MK, Hardlei TF, Brock B, Kreilgaard M, Gjedsted J. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations? Antimicrob Agents Chemother 2015;59:7018-26. [PMID: 26349823 DOI: 10.1128/AAC.01347-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
47 Jacobs A, Taccone FS, Roberts JA, Jacobs F, Cotton F, Wolff F, Creteur J, Vincent JL, Hites M. β-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. Antimicrob Agents Chemother 2018;62:e02534-17. [PMID: 29987138 DOI: 10.1128/AAC.02534-17] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
48 Ruiz J, Ferrada A, Salavert M, Gordon M, Villarreal E, Castellanos-Ortega Á, Ramirez P. Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia. Dose Response 2020;18:1559325819885790. [PMID: 32063809 DOI: 10.1177/1559325819885790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Sinnollareddy MG, Roberts JA. Pharmacodynamic Considerations in Critically Ill Patients. In: Rotschafer JC, Andes DR, Rodvold KA, editors. Antibiotic Pharmacodynamics. New York: Springer; 2016. pp. 537-60. [DOI: 10.1007/978-1-4939-3323-5_21] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Carlier M, Roberts JA, Stove V, Verstraete AG, Lipman J, De Waele JJ. A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. Antimicrob Agents Chemother 2015;59:4689-94. [PMID: 26014946 DOI: 10.1128/AAC.00409-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
51 Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther 2016;38:1930-47. [PMID: 27449411 DOI: 10.1016/j.clinthera.2016.06.015] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
52 Zhao Y, Xiao C, Hou J, Wu J, Xiao Y, Zhang B, Sandaradura I, Luo H, Li J, Yan M. C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem. Antibiotics 2022;11:670. [DOI: 10.3390/antibiotics11050670] [Reference Citation Analysis]
53 Wicha SG, Huisinga W, Kloft C. Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information. CPT Pharmacometrics Syst Pharmacol 2017;6:512-22. [PMID: 28378945 DOI: 10.1002/psp4.12197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
54 Bretonnière C, Leone M, Milési C, Allaouchiche B, Armand-Lefevre L, Baldesi O, Bouadma L, Decré D, Figueiredo S, Gauzit R, Guery B, Joram N, Jung B, Lasocki S, Lepape A, Lesage F, Pajot O, Philippart F, Souweine B, Tattevin P, Timsit JF, Vialet R, Zahar JR, Misset B, Bedos JP; Société de Réanimation de Langue Française (SRLF)., Société Française d’Anesthésie et de Réanimation (SFAR). Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric). Intensive Care Med 2015;41:1181-96. [PMID: 26077053 DOI: 10.1007/s00134-015-3853-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
55 Maimongkol P, Yonwises W, Anugulruengkitt S, Sophonphan J, Treyaprasert W, Wacharachaisurapol N. Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study. Int J Infect Dis 2022:S1201-9712(22)00253-3. [PMID: 35489632 DOI: 10.1016/j.ijid.2022.04.052] [Reference Citation Analysis]
56 Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011;37:632-8. [PMID: 21136037 DOI: 10.1007/s00134-010-2105-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
57 Andersen MG, Thorsted A, Storgaard M, Kristoffersson AN, Friberg LE, Öbrink-Hansen K. Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered? Antimicrob Agents Chemother 2018;62:e02306-17. [PMID: 29507062 DOI: 10.1128/AAC.02306-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
58 Kumta N, Heffernan AJ, Cotta MO, Wallis SC, Livermore A, Starr T, Wong WT, Joynt GM, Lipman J, Roberts JA. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. Antimicrob Agents Chemother. [DOI: 10.1128/aac.00142-22] [Reference Citation Analysis]
59 Giacobbe DR, Roberts JA, Abdul-Aziz MH, de Montmollin E, Timsit JF, Bassetti M. Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. Expert Rev Anti Infect Ther 2022. [PMID: 35385681 DOI: 10.1080/14787210.2022.2063838] [Reference Citation Analysis]
60 Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med 2017;43:1021-32. [PMID: 28409203 DOI: 10.1007/s00134-017-4780-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
61 MacVane SH, Kuti JL, Nicolau DP. Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2014;58:1359-64. [PMID: 24342637 DOI: 10.1128/AAC.01463-13] [Cited by in Crossref: 46] [Cited by in F6Publishing: 23] [Article Influence: 5.1] [Reference Citation Analysis]
62 Imburgia TA, Kussin ML. A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients. J Pediatr Pharmacol Ther 2022;27:214-27. [PMID: 35350159 DOI: 10.5863/1551-6776-27.3.214] [Reference Citation Analysis]
63 Braune S, König C, Roberts JA, Nierhaus A, Steinmetz O, Baehr M, Kluge S, Langebrake C. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. Crit Care 2018;22:25. [PMID: 29382394 DOI: 10.1186/s13054-018-1940-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
64 Win EE, Htun KW, Tragulpiankit P, Tangtrakultham S, Montakantikul P. The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing Escherichia coli in ICU Patients Using Monte Carlo Simulation. IDR 2022;Volume 15:439-53. [DOI: 10.2147/idr.s345385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Lan J, Wu Z, Wang X, Wang Y, Yao F, Zhao B, Wang Y, Chen J, Chen C. Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection. Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.xphs.2022.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Usman M, Frey OR, Hempel G. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. Eur J Clin Pharmacol 2017;73:333-42. [PMID: 27966034 DOI: 10.1007/s00228-016-2172-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
67 Zander J, Döbbeler G, Nagel D, Maier B, Scharf C, Huseyn-Zada M, Jung J, Frey L, Vogeser M, Zoller M. Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study. Crit Care 2016;20:79. [PMID: 27039986 DOI: 10.1186/s13054-016-1255-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
68 Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF; NeoMero Consortium. Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies. J Antimicrob Chemother 2018;73:1908-16. [PMID: 29684147 DOI: 10.1093/jac/dky128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
69 Heil EL, Nicolau DP, Farkas A, Roberts JA, Thom KA. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. Antimicrob Agents Chemother 2018;62:e01008-18. [PMID: 29967022 DOI: 10.1128/AAC.01008-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
70 Venugopalan V, Manigaba K, Borgert SJ, Cope J, Peloquin CA, Klinker KP. Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. Microbiol Insights 2018;11:1178636118804549. [PMID: 30349291 DOI: 10.1177/1178636118804549] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva JA, Pea F, Sjovall F, Timsit JF, Udy AA, Wicha SG, Zeitlinger M, De Waele JJ, Roberts JA; Infection Section of European Society of Intensive Care Medicine (ESICM)., Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID)., Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT)., Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.. Intensive Care Med 2020;46:1127-53. [PMID: 32383061 DOI: 10.1007/s00134-020-06050-1] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 41.0] [Reference Citation Analysis]
72 Abdulla A, Dijkstra A, Hunfeld NGM, Endeman H, Bahmany S, Ewoldt TMJ, Muller AE, van Gelder T, Gommers D, Koch BCP. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT). Crit Care 2020;24:558. [PMID: 32933574 DOI: 10.1186/s13054-020-03272-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
73 Derendorf H, Heinrichs T, Reimers T, Lebert C, Brinkmann A. Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics. GMS Infect Dis 2020;8:Doc17. [PMID: 32373442 DOI: 10.3205/id000061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Phe K, Heil EL, Tam VH. Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review. J Infect Dis 2020;222:S132-41. [PMID: 32691832 DOI: 10.1093/infdis/jiaa118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
75 Cheng V, Abdul-aziz MH, Roberts JA. Applying Antimicrobial Pharmacokinetic Principles for Complex Patients: Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation and Renal Replacement Therapy. Curr Infect Dis Rep 2021;23. [DOI: 10.1007/s11908-021-00757-y] [Reference Citation Analysis]
76 Vossen MG, Wenisch JM, Maier-Salamon A, Fritsch A, Saria K, Zuba C, Jilch S, Lemmerer R, Unger M, Jaehde U, Jäger W, Thalhammer F. Doripenem Treatment during Continuous Renal Replacement Therapy. Antimicrob Agents Chemother 2015;60:1687-94. [PMID: 26711775 DOI: 10.1128/AAC.01801-15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
77 Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010;54:804-10. [PMID: 19995927 DOI: 10.1128/AAC.01190-09] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
78 Wittau M, Scheele J, Kurlbaum M, Brockschmidt C, Wolf AM, Hemper E, Henne-Bruns D, Bulitta JB. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery. Antimicrob Agents Chemother 2015;59:6241-7. [PMID: 26248353 DOI: 10.1128/AAC.00259-15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
79 Benítez-Cano A, Luque S, Sorlí L, Carazo J, Ramos I, Campillo N, Curull V, Sánchez-Font A, Vilaplana C, Horcajada JP, Adalia R, Bermejo S, Samsó E, Hope W, Grau S. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care 2020;24:55. [PMID: 32066497 DOI: 10.1186/s13054-020-2763-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
80 de Velde F, de Winter BCM, Neely MN, Strojil J, Yamada WM, Harbarth S, Huttner A, van Gelder T, Koch BCP, Muller AE, On Behalf Of The Combacte-Net Consortium. Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients. Pharmaceutics 2021;13:2170. [PMID: 34959451 DOI: 10.3390/pharmaceutics13122170] [Reference Citation Analysis]
81 Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, Mueller BA. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. Antimicrob Agents Chemother 2014;58:1320-6. [PMID: 24323468 DOI: 10.1128/AAC.02090-12] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
82 Bilgrami I, Roberts JA, Wallis SC, Thomas J, Davis J, Fowler S, Goldrick PB, Lipman J. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010;54:2974-8. [PMID: 20479205 DOI: 10.1128/AAC.01582-09] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
83 Ollivier J, Carrié C, d'Houdain N, Djabarouti S, Petit L, Xuereb F, Legeron R, Biais M, Breilh D. Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance? Antimicrob Agents Chemother 2019;63:e02134-18. [PMID: 30602511 DOI: 10.1128/AAC.02134-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
84 Berry AV, Kuti JL. Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man. Front Pharmacol 2022;13:833189. [DOI: 10.3389/fphar.2022.833189] [Reference Citation Analysis]
85 De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, Leroux-Roels I, Hoste E, Depuydt P, Decruyenaere J, Verstraete AG. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 2014;40:380-7. [PMID: 24356862 DOI: 10.1007/s00134-013-3187-2] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 9.2] [Reference Citation Analysis]
86 Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients. Antimicrob Agents Chemother 2018;62:e01150-18. [PMID: 30104278 DOI: 10.1128/AAC.01150-18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
87 Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, Munita JM, Boté A, Gasch O, Nuvials X, Dinh A, Shaw R, Lomas JM, Torres V, Castón J, Araos R, Abbo LM, Rakita R, Pérez F, Aitken SL, Arias CA, Martín-Pena ML, Colomar A, Núñez MB, Mensa J, Martínez JA, Soriano A. Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infect Dis 2019;6:ofz416. [PMID: 31660373 DOI: 10.1093/ofid/ofz416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
88 Bédos J, Allaouchiche B, Armand-lefèvre L, Baldesi O, Bouadma L, Decré D, Figueiredo S, Gauzit R, Guery B, Joram N, Jung B, Lasocki S, Lepape A, Lesage F, Pajot O, Philippart F, Souweine B, Tattevin P, Timsit J, Zahar J, Bretonnière C, Leone M, Milési C, Misset B. Stratégies de réduction de l’utilisation des antibiotiques à visée curative en réanimation (adulte et pédiatrique). Réanimation 2014;23:558-82. [DOI: 10.1007/s13546-014-0916-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
89 Cimino C, Burnett Y, Vyas N, Norris AH. Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis. Drugs 2021;81:555-74. [PMID: 33591549 DOI: 10.1007/s40265-021-01469-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Kang Y, Zhou Q, Cui J. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China. J Glob Antimicrob Resist 2021;27:67-71. [PMID: 34428596 DOI: 10.1016/j.jgar.2021.07.020] [Reference Citation Analysis]
91 Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB. Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrob Agents Chemother 2017;61:e02642-16. [PMID: 28264846 DOI: 10.1128/AAC.02642-16] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
92 Chai MG, Cotta MO, Abdul-Aziz MH, Roberts JA. What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit? Pharmaceutics 2020;12:E638. [PMID: 32645953 DOI: 10.3390/pharmaceutics12070638] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
93 Mader MM, Czorlich P, König C, Fuhrmann V, Kluge S, Westphal M, Grensemann J. Intrathecal penetration of meropenem and vancomycin administered by continuous infusion in patients suffering from ventriculitis-a retrospective analysis. Acta Neurochir (Wien) 2018;160:2099-105. [PMID: 30242495 DOI: 10.1007/s00701-018-3680-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
94 Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model. Antimicrob Agents Chemother 2018;62:e02055-17. [PMID: 29437610 DOI: 10.1128/AAC.02055-17] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
95 Hanberg P, Lund A, Søballe K, Bue M. Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis: An animal study. Bone Joint Res 2019;8:313-22. [PMID: 31463039 DOI: 10.1302/2046-3758.87.BJR-2018-0308.R1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
96 Cojutti PG, Gatti M, Rinaldi M, Tonetti T, Laici C, Mega C, Siniscalchi A, Giannella M, Viale P, Pea F. Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. Front Pharmacol 2021;12:781892. [PMID: 34955851 DOI: 10.3389/fphar.2021.781892] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín-Loeches I. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother 2015;59:5520-8. [PMID: 26124172 DOI: 10.1128/AAC.00712-15] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 5.9] [Reference Citation Analysis]
98 Wang Y, Chen W, Huang Y, Wang G, Li Z, Yan G, Chen C, Lu G. Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support. Front Pharmacol 2021;12:699191. [PMID: 34504424 DOI: 10.3389/fphar.2021.699191] [Reference Citation Analysis]